Lung cancer drug combo trial pulled before it began

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Histologically confirmed diagnosis of NSCLC (squamous or nonsquamous) with KRAS G12C mutation. * Diagnostic core biopsy specimens must be reviewed by a faculty pathologist at the enrolling/treating institution, and biopsy tissue must be available for further biomarker evaluation. If no archived tissue is available, patients will require a repeat biopsy prior to initiation of study treatment. See section 6.5.1 and lab manual for details of pretreatment biopsy tissue required. * KRAS G12C mutation determined by any CLIA-certified testing platform on patient tumor tissue or plasma sample. * Stage IB-IIIA NSCLC * T2aN0, T3N0, T1-2N1, T3-4N1, T1-2N2. This includes T2aN0 tumors ≥3 cm. Subjects with N3 nodal involvement are not included. * Primary resection option for potential cure as assessed by a faculty surgeon at treating institution. * ECOG performance status 0-1 (See Appendix B) * Adequate organ function within the screening period as follows: * Leukocytes ≥ 2,000/mm3 * Absolute neutrophil count (ANC) ≥ 1000/mm3 * Platelet count ≥ 100,000/mm3 * Hemoglobin ≥ 9 g/dL * Creatinine ≤ 1.5 x institutional upper limit of normal (ULN) or creatinine clearance (CrCl) ≥60 mL/min * Total Bilirubin ≤ 1.5 x institutional ULN (except subjects with Gilbert Syndrome, who can have total bilirubin \< 3.0 mg/dL) * AST(SGOT), ALT(SGPT), and alkaline phosphatase ≤ 3 x institutional ULN * Pulmonary Function Testing to include DLCO must be performed to determine feasibility of surgical resection. * Women of child-bearing potential (WOCBP): * Agree to use contraception while participating in this study, and for a period of 6 months following last dose of Adagrasib or nivolumab, as effects of these agents on the developing human fetus are unknown. Men whose partner is a WOCBP must also agree to use contraception during this period. * Negative pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within two weeks of registration. * Women must not be breastfeeding or plan to breastfeed for the duration of therapy or 6 months after. * Completed informed consent process, including signing IRB/EC-approved informed consent form. * Willing and able to comply with clinical trial instructions and requirements. Subjects must be competent to report AEs, understand the drug dosing schedule, and use of medications to control AEs. Exclusion Criteria: * Patients presenting with any of the following will not be included in the study: * NSCLC not amenable to curative intent resection based on evaluation by faculty surgeon at treating institution. * This includes any patient with pathologically confirmed N3 disease. * Prior systemic treatment for lung cancer including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS G12C mutation. * Prior thoracic radiation. * Any concurrent malignancies for which active therapy is being received. * Exceptions: non-melanoma skin cancers; in situ dysplasia of the bladder, gastric, breast, colon, or cervix * Brain metastases at time of screening. * All patients must have brain imaging prior to enrollment (MRI brain or CT brain with contrast preferred). * Active or prior documented autoimmune or inflammatory disease as follows (Arm B only): * Medically relevant autoimmune disease requiring systemic treatment within 2 years prior to the first dose of study treatment. * Systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration (Arm B only). Inhaled or topical steroids are permitted. * Adrenal replacement doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. * Major surgery within 4 weeks prior to first dose of study treatment. * History of allogeneic transplant or primary immunodeficiency. * Uncontrolled human immunodeficiency virus (HIV) infection or acute or chronic hepatitis B or C infection. * Patients treated for hepatitis C with no detectable viral load and patients treated for HIV with no detectable viral load for at least 1 month while on a stable regimen of agents that are not strong inhibitors of CYP3A4 are permitted. * HIV testing is not required in absence of clinical suspicion of HIV. * Any of the following cardiac abnormalities: * Unstable angina pectoris or myocardial infarction within the past 6 months. * Symptomatic or uncontrolled atrial fibrillation within the past 6 months. * Congestive heart failure ≥NYHA Class 3 within the past 6 months. * QTc ≥ 480 msec in screening ECG measured using standard institutional method or history of familial long QT syndrome. * Ongoing need for a medication with any of the following characteristics that cannot be switched to alternative treatment prior to study entry (see Appendix D): known risk of Torsades de Pointes; substrate of CYP3A with narrow therapeutic index; strong inducer or inhibitor of CYP3A and/or P-gp; strong inhibitor of BCRP; and proton pump inhibitors. * History of stroke or transient ischemic attack within 6 months prior to first dose of study treatment. * History of intestinal disease or major gastric surgery likely to alter absorption of study treatment or inability to swallow oral medications. * Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events. * Women who are pregnant or nursing. * Prisoners or subjects who are involuntarily incarcerated or compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness. * Receipt of a live vaccine within 30 days prior to first dose of study treatment.